Cargando…
The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
OBJECTIVES: Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DX...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670367/ https://www.ncbi.nlm.nih.gov/pubmed/29066534 http://dx.doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1 |
_version_ | 1783276011247370240 |
---|---|
author | Jin, A. Cobb, J. Hansen, U. Bhattacharya, R. Reinhard, C. Vo, N. Atwood, R. Li, J. Karunaratne, A. Wiles, C. Abel, R. |
author_facet | Jin, A. Cobb, J. Hansen, U. Bhattacharya, R. Reinhard, C. Vo, N. Atwood, R. Li, J. Karunaratne, A. Wiles, C. Abel, R. |
author_sort | Jin, A. |
collection | PubMed |
description | OBJECTIVES: Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DXA) scanning may show a gain in bone density, the impact of this class of drug on mechanical properties remains unclear. We therefore sought to quantify the mechanical strength of bone treated with BP (oral alendronate), and correlate data with the microarchitecture and density of microcracks in comparison with untreated controls. METHODS: Trabecular bone from hip fracture patients treated with BP (n = 10) was compared with naïve fractured (n = 14) and non-fractured controls (n = 6). Trabecular cores were synchrotron scanned and micro-CT scanned for microstructural analysis, including quantification of bone volume fraction, microarchitecture and microcracks. The specimens were then mechanically tested in compression. RESULTS: BP bone was 28% lower in strength than untreated hip fracture bone, and 48% lower in strength than non-fractured control bone (4.6 MPa vs 6.4 MPa vs 8.9 MPa). BP-treated bone had 24% more microcracks than naïve fractured bone and 51% more than non-fractured control (8.12/cm(2) vs 6.55/cm(2) vs 5.25/cm(2)). BP and naïve fracture bone exhibited similar trabecular microarchitecture, with significantly lower bone volume fraction and connectivity than non-fractured controls. CONCLUSION: BP therapy had no detectable mechanical benefit in the specimens examined. Instead, its use was associated with substantially reduced bone strength. This low strength may be due to the greater accumulation of microcracks and a lack of any discernible improvement in bone volume or microarchitecture. This preliminary study suggests that the clinical impact of BP-induced microcrack accumulation may be significant. Cite this article: A. Jin, J. Cobb, U. Hansen, R. Bhattacharya, C. Reinhard, N. Vo, R. Atwood, J. Li, A. Karunaratne, C. Wiles, R. Abel. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res 2017;6:602–609. DOI: 10.1302/2046-3758.610.BJR-2016-0321.R1. |
format | Online Article Text |
id | pubmed-5670367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-56703672017-11-15 The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density Jin, A. Cobb, J. Hansen, U. Bhattacharya, R. Reinhard, C. Vo, N. Atwood, R. Li, J. Karunaratne, A. Wiles, C. Abel, R. Bone Joint Res Research OBJECTIVES: Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DXA) scanning may show a gain in bone density, the impact of this class of drug on mechanical properties remains unclear. We therefore sought to quantify the mechanical strength of bone treated with BP (oral alendronate), and correlate data with the microarchitecture and density of microcracks in comparison with untreated controls. METHODS: Trabecular bone from hip fracture patients treated with BP (n = 10) was compared with naïve fractured (n = 14) and non-fractured controls (n = 6). Trabecular cores were synchrotron scanned and micro-CT scanned for microstructural analysis, including quantification of bone volume fraction, microarchitecture and microcracks. The specimens were then mechanically tested in compression. RESULTS: BP bone was 28% lower in strength than untreated hip fracture bone, and 48% lower in strength than non-fractured control bone (4.6 MPa vs 6.4 MPa vs 8.9 MPa). BP-treated bone had 24% more microcracks than naïve fractured bone and 51% more than non-fractured control (8.12/cm(2) vs 6.55/cm(2) vs 5.25/cm(2)). BP and naïve fracture bone exhibited similar trabecular microarchitecture, with significantly lower bone volume fraction and connectivity than non-fractured controls. CONCLUSION: BP therapy had no detectable mechanical benefit in the specimens examined. Instead, its use was associated with substantially reduced bone strength. This low strength may be due to the greater accumulation of microcracks and a lack of any discernible improvement in bone volume or microarchitecture. This preliminary study suggests that the clinical impact of BP-induced microcrack accumulation may be significant. Cite this article: A. Jin, J. Cobb, U. Hansen, R. Bhattacharya, C. Reinhard, N. Vo, R. Atwood, J. Li, A. Karunaratne, C. Wiles, R. Abel. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res 2017;6:602–609. DOI: 10.1302/2046-3758.610.BJR-2016-0321.R1. 2017-11-04 /pmc/articles/PMC5670367/ /pubmed/29066534 http://dx.doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1 Text en © 2017 Jin et al. This is an open-access article distributed under the terms of the Creative Commons Attributions licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited. |
spellingShingle | Research Jin, A. Cobb, J. Hansen, U. Bhattacharya, R. Reinhard, C. Vo, N. Atwood, R. Li, J. Karunaratne, A. Wiles, C. Abel, R. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
title | The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
title_full | The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
title_fullStr | The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
title_full_unstemmed | The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
title_short | The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
title_sort | effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670367/ https://www.ncbi.nlm.nih.gov/pubmed/29066534 http://dx.doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1 |
work_keys_str_mv | AT jina theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT cobbj theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT hansenu theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT bhattacharyar theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT reinhardc theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT von theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT atwoodr theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT lij theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT karunaratnea theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT wilesc theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT abelr theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT jina effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT cobbj effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT hansenu effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT bhattacharyar effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT reinhardc effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT von effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT atwoodr effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT lij effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT karunaratnea effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT wilesc effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity AT abelr effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity |